Atlas Trials

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

Clinical trial NCT03285412 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03285412
Sponsor
Massachusetts General Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2017-12-12
Primary completion
2026-04-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.